ÂÜÀòÂÒÂ×

Jan is an Executive Chairman at DEM Biopharma, and a member of the Board of Directors at Zentalis Pharmaceuticals (Nasdaq:ZNTL). Previously, he was the CEO of Trillium Therapeutics (Nasdaq:TRIL), a clinical stage immuno-oncology company, where he led a highly successful, 360-degree turn-around that produced a leading CD47 drug candidate, while taking the company from a $16M valuation to a $2.3B buy-out by Pfizer in two years. Prior to that, Jan was the CEO of Tal Medical, a private, clinical stage neuroscience company; a partner in the life sciences practice at Bain & Company, Boston; and a manager at Price Waterhouse Corporate Finance in London, UK and Vienna, Austria. He holds a PhD in economics from the University of Economics in Slovakia, and an MBA from Harvard Business School.